Kashiv BioSciences Private Limited Secures INR 648 Cr Financing from Union Bank of India to Expand Biologics Manufacturing Facility in Gujarat 

Key Highlights: 

• Kashiv BioSciences secured INR 648 crore in financing from Union Bank of India to expand its biologics manufacturing facility in Pipan near Ahmedabad, Gujarat. The investment will support the development of a large-scale, single-use commercial manufacturing facility aimed at strengthening India’s biopharmaceutical production capacity. 
• Once fully operational, the facility is expected to support manufacturing capacity of up to 50,000L and will utilize advanced single-use bioprocessing technologies to produce high-quality biologics and specialty pharmaceuticals for global markets, including the U.S., Canada, and Europe. 
• The expansion is expected to enhance technical capabilities, improve global competitiveness, and generate high-value employment across scientific, technical, and operational roles while supporting initiatives under the Gujarat State Biotechnology Mission aimed at strengthening India’s biotechnology manufacturing ecosystem. 

Implications:  

Kashiv’s scaling challenges Biocon/Serum Institute dominance in India’s $15B+ biologics CDMO space (18% CAGR), capturing 10-15% complex molecule share via single-use efficiency. 
50,000L capacity accelerates U.S./EU tenders, pressuring China-dependent supply chains  
Strengthens India’s nephrology/oncology export hub status 

Source: Businesswire | Image: Kashiv Biosciences